Health
Top 5 APAC Countries for Legal Cannabis
The global legal cannabis market is projected to reach US$97.35 billion by the end of 2026. More than 50 countries worldwide now permit access to regulated medical marijuana, and several nations–like South Africa and Mexico–have even legalised cultivation for personal use. While much of this development has been concentrated in Europe and the US, several nations in Asia-Pacific have also recently shifted towards greater tolerance. We’ve identified the 5 nations in the region that offer the greatest access to legal marijuana.
1. AUSTRALIA
Australia ranks as APAC’s most marijuana-accessible nation both because of its booming medical cannabis market and its legalisation, in part, of recreational use in some jurisdictions. No other nation in the region has laws quite so liberal–though rifts between commonwealth and district laws may lead to conflict in the future.
Medical Use & Cannabis Research
In the past decade, Australian support for medical marijuana has increased continuously, rising from 69% in 2013 to 85% in 2016, when the growth & cultivation of cannabis for medical and scientific purposes finally became legal. There are now over 1,000 registered patients receiving medical marijuana products by prescription, and this number is projected to surge to 400,000 by 2028. Australia’s cannabis market has grown accordingly, with an estimated value of A$6.3 billion in 2018 alone. In fact, just the top 20 listed cannabis companies in the nation–led by industry leaders Elixinol Global, Cann Group and Althea–have a market capitalisation of A$1.8 billion.
Nonetheless, medical cannabis isn’t accessible to everyone, even those with qualifying medical conditions and an authorised prescription. This is because medical marijuana products are not covered under Australia’s Pharmaceutical Benefits Scheme; all medications must be paid for out-of-pocket. Unfortunately, such costs can quickly become prohibitive. Market research by Cannabis Access Clinics estimates that Australian patients spend an average of A$370/month on medical marijuana products, with epilepsy patients paying an even higher A$1,000/month on average. Given single Australians under 35 years old spend about A$849/week total, such high expenditures on marijuana could amount to 25%+ of an epileptic patient’s monthly budget.
Recreational Use & Drug Culture
Unlike in any other APAC nation, the recreational use of marijuana is actually legal in certain districts in Australia. More specifically, the Australia Capital Territory (ACT) became the first jurisdiction to legalise personal use in a bill passed in September 2019. The bill takes effect at the end of January 2020 and will allow adults to grow up to 2 cannabis plants at home and possess up to 50g on their person. Other districts, like South Australia and the Northern Territory, have decriminalised recreational use, limiting penalties to civil fines.
District laws conflict with federal laws, however, which may ultimately challenge the validity of such “legalisation.” The Australian Commonwealth has neither legalised nor decriminalised recreational marijuana use to date. This means that an individual caught with cannabis may not be penalised by district police in certain territories, but could still be charged and jailed if caught by a federal official. Even still, marijuana is the most widely used illicit drug in Australia and tolerance for its recreational use has grown in the past several years (9.8% in 2013 to 14.5% in 2016). This positive momentum may extend decriminalisation and legalisation to new districts. In fact, a poll last year found that 59% of Tasmanians also supported the decriminalisation of recreational marijuana.
Laws, Penalties & Arrests
Cannabis law and retributional policy vary significantly across Australia, as each district has its own policies, as does the federal Commonwealth. While federal law has ultimate authority, jurisdictional legislation stands unless (or until) questioned. In all cases, individuals can be charged with possession or supply/trafficking (assumed when the possessed amount is above a set threshold), and may receive a prison sentence, civil penalty fine, or both. Districts that have decriminalised–or even legalised–recreational use can still charge people who distribute drugs, consume them in public, or who don’t follow other limitations. While fines may be amongst the highest for the Commonwealth, perpetrators in Queensland can be imprisoned without alternative. Overall–taking other APAC nations into consideration–Australian penalties are generally expensive, but milder in terms of prison sentencing.
Final Verdict:
Ultimately, Australia is the only APAC nation where an individual can legally consume marijuana for both medicinal and recreational purposes. While laws are still in place that limit access and punish misuse, legalisation and decriminalisation have continued to extend further across the nation. Perhaps the most prohibitive factor is the cost of medical cannabis products, which may make it harder for Australia’s less affluent patients to obtain medications they need.
2. NEW ZEALAND
While accessibility of and tolerance for marijuana use in New Zealand was only recently realised on the national scale, momentum towards legalisation has escalated rapidly. In fact, domestic cultivation of medical cannabis will be permitted as of April 2020 and citizens are already set to vote on legalisation for recreational use. If Parliament follows through and approves such a bill, New Zealand will be the first APAC nation to legalise cannabis for both medical and personal consumption.
Medical Use & Cannabis Research
New Zealand’s Misuse of Drugs (Medicinal Cannabis) Amendment Act–which first came into effect just over a year ago, in December 2018–will be fully operational by the end of March 2020. The legislation allows consumers to access CBD medical products with a prescription from a licenced professional. Research suggests that an estimated 25,000 individuals could qualify for treatment in 2018 alone.
Unfortunately, as in Australia, New Zealand’s government (specifically the Pharmaceutical Management Agency–PHARMAC) does not subsidise any medical cannabis products. This means that patients must pay for their medications out-of-pocket. Additionally, the right to cultivate and extract cannabis domestically is still limited to medical and scientific research institutions, which cannot sell products commercially. Instead, patients must purchase imported products that are often pricey and face limited competition.
Nonetheless, this restriction on domestic cultivation and commercial production is about to change. In April 2020, companies that currently have licences to grow cannabis for R&D purposes will be able to apply for permits for commercial cultivation and manufacturing licenses. Many of these companies have already raised millions of dollars in funding and are leveraging these investments to develop “next generation medicinal cannabinoid products” and build industrial production facilities. Paul Manning, director of Helius Therapeutics in Auckland, claims the company could easily produce $700 million worth in products from its current warehouse. With the loosening of restrictions on domestic production, New Zealand’s local medical marijuana industry will have the capacity to grow rapidly and eclipse that of any other APAC nation. In the meantime, popular support for medical marijuana remains strong, with 87% of New Zealanders supporting its use for pain treatment in 2018.
Recreational Use & Drug Culture
Even as New Zealand’s medicinal marijuana industry is yet to fully actualise, the nation has already moved towards legalising the drug for recreational use. Citizens will vote in a referendum on the proposed Cannabis Legislation and Control Bill in 2020. The bill would allow residents aged 20 years and up to grow up to 2 cannabis plants on private property (up to 4 per household), possess up to 14g of dried cannabis in a public space, and to purchase recreational cannabis from approved stores. The legislation would also restrict underage use and possession and limit advertising efforts, in an attempt to minimise harm overall.
Residents will vote “yes” or “no” on the cannabis bill, which will be on the same ballot as the 2020 General Election. The referendum is said to be binding, because the current Parliament has agreed to honour the results of the vote and enact the bill if residents vote to do so. However, many have pointed to a loophole that could complicate outcomes. While the current government has agreed to this binding referendum, a new government–if different than the current–would not be bound to do so. As the referendum will be on the General Election ballot, it’s quite possible that the government might change. If a new party takes power, they may choose not to follow the will of the people.
In either case, recreational cannabis is already quite popular in New Zealand. In fact, research from Auckland University’s Alcohol and Public Health Research Unit revealed that more than half of New Zealanders aged 15-29 have tried marijuana, and about a third describe themselves as active users. Nonetheless, a 2019 Newshub-Reid Research Poll found that 48% of New Zealanders don’t agree with legalising marijuana for recreational use, with 41.7% agreeing and 10.4% not stating a preference. The national split in sentiment may further complicate the outcome of New Zealand’s 2020 referendum. Even still, few other APAC countries have even brought the question of recreational legalisation to a national stage.
Laws, Penalties & Arrests
Even though the non-regulated use of marijuana is still illegal in New Zealand, penalties are far less strict than those found elsewhere and policing is focused on harm minimisation. In fact, an individual possessing less than 5g of cannabis is likely to receive 3 months and/or a NZ$500 fine (approx. US$335) at most. In Australia, a Queensland resident could receive as much as 15 years imprisonment, or be charged a A$68,000 (approx. US$47,600) fine at the federal level. Even more, selling or supplying cannabis could lead to the death penalty in South Korea or Singapore–much harsher than the 8 year sentence for supplying in New Zealand.
Final Verdict:
Ultimately, New Zealand is poised at the edge of becoming APAC’s most marijuana-accesible nation. If its cannabis referendum bill is enacted into law, it will be the only country to have fully legalised recreational marijuana use. Even still, the nation’s growing tolerance is reflected in its comparatively mild laws. The current climate will further improve with the removal of domestic restrictions on cultivation in April 2020, allowing local New Zealand medical cannabis companies to expand and thrive.
3. THAILAND
Thailand is known as a regional leader in making medical marijuana accessible to its citizens. In fact, its move to legalise medicinal use is largely thought to have opened the door for other APAC nations to follow-suit. Unlike other nations, however, Thailand’s decisions have been predominantly driven by economic factors, with domestic commercialisation of the medical marijuana industry just on the horizon. Nonetheless, the Thai government’s recent war on drugs has stifled any social outcries for recreational legalisation.
Medical Use & Cannabis Research
Medical cannabis was first legalised in Thailand in December 2018, and its first clinic opened in Ang Thong in November 2019. The government–specifically, its Ministry of Public Health–began distributing cannabis-infused medicines to hospitals and licenced traditional medicine practitioners that same year. Since legalisation, the Thai government has continuously sponsored the development of new formulas for traditional medical applications. More than 15,000 bottles of cannabis oil have already been produced and distributed to date, 16 treatments have been approved for use, and over 2,900 practitioners have been licenced to prescribe medical marijuana to patients. Thailand’s Government Pharmaceutical Organisation [GPO] aims to cultivate and harvest enough cannabis to produce 1 million 5ml bottles of cannabis oil by February 2020.
Despite this strong forward push, Thailand limits domestic cultivation to government and research institutions, and these products can be used for non-commercial use only. This effectively limits supply and reduces patients’ access to medical marijuana products. To address this imbalance, the Ministry of Public Health recently drafted a rule that would allow for commercial production of cannabis-infused medications, which could be used for local consumption (meeting patients’ needs) or even exported abroad. Marijuana grows very easily in Thailand’s tropical climate–some have identified it as a potential “cash crop”–and loosening commercial restrictions could promote domestic growth and boost the economy. Even more, the proposed law would limit foreign ownership of such commercial companies to just 33%. If the law–which is currently under review by the Council of State–passes, it will likely come into effect by March 2020.
It’s also worth mentioning that Thai’s Bhumjaithai Party has recently pushed for even further reform. The party has drafted a bill that would permit households to grow up to 6 cannabis plants at home, and then sell these plants back to the government or local medical practitioners for a profit. According to the party, this schema would dramatically benefit locals’ economic wellbeing while redressing supply issues. However, the bill would need at least 500 legislators’ support to succeed.
Recreational Use & Drug Culture
Thailand’s fairly recent war on drugs has made recreational use of cannabis for the most part taboo. The war, launched by Prime Minister Thaksin Shinawatra, was launched in February 2003 and was aimed at suppressing both use and trafficking. However, many view the policy as a cover for arbitrary killings. In fact, an estimated 2,800 such killings are thought to have taken place within the first 3 months. An official investigation in 2007 found that the majority of individuals killed during the war had no connection to drugs. Nonetheless, the violence had a strong impact. Today, recreational use is still harshly condemned by the government, and there are no real challenges to such laws.
This does not mean that there is no personal consumption of cannabis in Thailand, however. There are many accounts of bars and taverns in the region, especially near the nation’s border with Cambodia, that advertise “happy” foods and drinks. This labelling indicates the item contains marijuana. Again, just as Thailand’s tropical climate makes it very easy to cultivate cannabis for medical commercial use, it also enables non-licenced individuals to grow plants as well.
Laws, Penalties & Arrests
Penalties for illicit marijuana possession and supply are for the most part stricter than those in Australia and New Zealand. Prison sentences begin at 2 years, but can scale up to 15 years with additional fines. While there is some variability in enforcement reported, likely based on the influence of an estimated 50 organised crime groups in Thailand, policing is still quite strong. In fact, 26.6 tonnes of dried cannabis were seized in 2016, up from 11.7 tonnes in 2006.
Nonetheless, marijuana is far from the “drug of choice” in Thailand, where 75% of identified users and addicts take Yaba (a combination of meth and caffeine) and 7% take Ice (crystal meth), compared to just 5% for cannabis. The estimated population using marijuana illicitly in Thailand has increased since the end of the drug war, but is still quite low as a percentage of the total population (3.7% in 2016).
Final Verdict:
While Thailand appears economically driven to dramatically open up its medical marijuana industry, personal use is seen as forbidden, and is unlikely to be legalised in the near future. Even so, commercial changes could transform Thailand into a regional powerhouse and disrupt APAC’s entire medical marijuana industry.
4. SOUTH KOREA
South Korea is surprisingly amongst APAC’s most marijuana-accessible countries–though policies and culture certainly limit consumers’ ability to use or even afford products. While medical cannabis was recently legalised, recreational use is still illicit and penalised harshly.
Medical Use & Cannabis Research
The use of medical marijuana was legalised by South Korea’s National Assembly in 2018–somewhat surprisingly, given the country’s generally conservative nature. While innovative for the region, the legalising amendment still has many restrictions that limit the accessibility of medications. First, permission to use medical cannabis is granted only on a case-by-case basis, requiring government review and approval. Only patients with specific diseases are eligible for treatment (HIV/AIDS, cancer, multiple sclerosis, and epilepsy, including Dravet syndrome and Lennox-Gastaut syndrome), and there must be no other medicine substitute available within the country. Patients must submit an application, accompanied by a doctor’s note, before they are finally prescribed medication through the Korean Orphan & Essential Drug Center [KODC].
Unfortunately, medical marijuana products can only be imported from overseas, and are not covered by medical insurance. This, as in other APAC countries, translates to extremely high prices that many patients may not be able to afford. Only a few products can be legally imported–Sativex, Epidiolex, Marinol and Cesamet–and these medications are all approved by foreign health regulatory agencies and are globally expensive. For example, a 100ml bottle of Epidiolex costs about US$1,235 in the United States, which is only slightly cheaper than the cost of a 100ml bottle of cannabidiol oral solution in Korea (1.5 million won, or US$1,358). The Korean Cannabinoid Association [KCA] estimates that one year’s worth of medical marijuana treatment can add up to 36 million won (over US$32,500).
As a result of such regulations, the medical marijuana industry within South Korea is not especially strong. Loosening restrictions could allow for greater product research and development and open the doors for new local start-ups, which could ultimately help to reduce medication pricing.
Recreational Use & Drug Culture
Recreational marijuana is taboo in South Korea; in fact, some propaganda efforts have moved to associate cannabis with vestigial Japanese colonial rule and North Korean tactics to “perturb” the country. While there are occasional celebrity arrests for drug use, such acts are quickly condemned as morally indecent. According to Kim Hyeong-gun, head of the Seoul Addiction Institute of Psychotherapy, “Korean society does not approach drug addicts with the goal of healing them… If one uses drugs, society immediately views them as criminals.” While drug arrests overall have increased since 2003, the percentage as per the total population is still remarkably low.
Laws, Penalties & Arrests
Despite its recent legalisation of medical marijuana, South Korea is still very strict in punishing those who consume or sell the drug illegally. Perpetrators can not only be charged up to 5 years of prison and hard labour just for personal possession, they can even be sentenced to death for importing or exporting the drug for profit. Of the APAC nations that allow at least some legal access to cannabis, South Korea is one of the very few with such harsh penalties. This is at least partially driven by the country’s goal of becoming a drug-free nation, and projecting that image to the world.
Final Verdict:
South Korea, while more open than many other APAC nations, still is quite restrictive in granted access to medical marijuana. Products, which must be imported, can be prohibitively expensive, and retribution for recreational use is notably harsh. At the moment, South Korea’s policies, culture and restrictions prevent marijuana from becoming easily accessible–legally or otherwise.
5. SINGAPORE
Singapore may be known as one of the strictest anti-drug countries in the world, but it’s actually a bit more permissive and exploratory than expected. While the use of raw marijuana is expressly rejected and harshly penalised, the government is actively funding the development of synthetic cannabinoids for use in select medical treatments.
Medical Use & Cannabis Research
Singapore is generally known to have some of the strictest drug policies not just in Asia-Pacific, but in the world. Even so, the nation recently broke ground by funding scientific research and development of synthetic CBD for prescription medication. The initiative, channeled through the National Research Foundation [NRF], is dedicated to artificially developing cannabinoids through selective genetic transfer, allowing engineers to create therapeutic compounds without every having to grow cannabis plants. This is especially important as cultivation of marijuana in Singapore is still strictly illegal. These synthetic cannabinoids will then be used to develop new treatments for Alzheimer’s, Parkinson’s Disease and more.
In addition to this funding and support for product development, Singapore has also opened the door to legal use of medical marijuana within the country. Recently, the government approved access to medical marijuana for a patient for the first time. The patient, who had drug-resistant epilepsy, was given a 1-year prescription, likely of Epidiolex (the only pharmaceutical grade cannabinoid medication approved by the US FDA). Receiving the prescription required government approval by the Ministry of Home Affairs [MHA], Health Sciences Authority [HSA], Central Narcotics Bureau [CNB], and Ministry of Health [MOH]. This case is important because it not only offers a precedent for future prescriptions, but also reflects the active importation of a pharmaceutical cannabinoid product. Such imports are legal–but only after the company, its manufacturers, and the corresponding products have been rigorously reviewed and approved by the HSA.
Recreational Use & Drug Culture
As mentioned, Singapore has a strict, zero-tolerance policy towards illicit drug use, including for marijuana. Perhaps due to these strict penalties, recreational use–and support for use–are quite low. In fact, a YouGov survey found that only 14% of Singaporeans think that marijuana should be legalised for personal use, while 67% do not support such a measure.
Laws, Penalties & Arrests
In Singapore, merely possessing cannabis can lead to a 10 year prison sentence, and selling or trafficking can be punished by death. These penalties are amongst the strictest in Asia-Pacific, both amongst nations where marijuana is measurably accessible as well as countries where the drug is forbidden altogether. In addition, perpetrators may even face public canings for their crime, which stands out from punishments administered by other nations.
Final Verdict:
Singapore is certainly not known for its open tolerance for drug use. In fact, as if to clarify its stance after funding synthetic CBD research and development, the government reiterated that raw, unprocessed cannabis is not safe to use and can be both addictive and harmful. Instead, there should be a focus on therapeutic, cannabinoid compounds, which are already included in some medications and can be prescribed within the country. This suggests that Singapore may be open to expanding research and developing new medications, but is unlikely to commercialise production or loosen recreational restrictions anytime soon.
OTHER REGIONAL PLAYERS
Philippines
Many immediately associate the Philippines with its violent and ongoing war on drugs, spearheaded by President Rodrigo Duterte. Nonetheless, the use of medical marijuana is technically legal within the state–though there are so many barriers to access that it’s generally viewed as inoperative. There’s no legal supply within the country, and import measures are incredibly strict. A bill that would broaden access and create a Medical Cannabis Compassionate Center was approved by the House of Representatives in early 2019. However, the proposal was shut down by Duterte once it reached the Senate. In a subsequent press briefing, the President responded, “Not during my time,” indicating that access to medical marijuana is unlikely to broaden until there’s a change in office.
Malaysia
Neither medical nor recreational marijuana use is currently legal in Malaysia, and the nation is known for its strict penalties against drug offenses. However, Malaysia is also approaching greater tolerance on all of these fronts. In February 2019, Deputy Health Minister Dr Lee Boon Chye stated that the government would consider medical cannabis products that were shown to be “safe and effective for use for certain conditions.” The government may also be working with cannabis company THC Global Group Ltd to develop policy framework for eventual medical legalisation.
At the same time, the government is also moving to decriminalise (but not legalise) personal use of the drug. Health Minister Datuk Seri Dr Dzulkefly Ahmad recently stated, “Malaysia is about to embark on a significant game-changer policy of decriminalisation of drug addicts and addiction”, and “an addict shall be treated as a patient (not as a criminal), whose addiction is a disease we would like to cure.” The Malaysian government is even moving to abolish its current death penalty for drug offenses.
Japan
Japan also has not truly legalised medical or recreational marijuana use. While it is legal to import CBD oil, products must have 0% THC (the psychoactive component of cannabis). Prescribing or consuming natural cannabis is strictly forbidden.
STANDARDISED CHARTS FOR COMPARISON
Below, we’ve combined the legal status for medical and recreational cannabis usage by country for easy comparison. Legislation regarding recreational legalisation is currently pending in New Zealand, as a referendum vote is underway. While medical cannabis usage is legal in South Korea and Singapore, applications are narrow and may not be fully utilised by governing parties.
The table below compares maximum fines for cannabis possession and supply or trafficking, standardised to USD for parallel reference. Possession is considered supply or trafficking after a minimum quantity threshold is reached, which varies from country to country. In many cases, possession and trafficking can be penalised with a fine, prison sentence, or both.
The following table compares the maximum prison sentence for cannabis possession and supply or trafficking by country. In South Korea and Singapore, drug trafficking can result in life imprisonment or even the death penalty. Even still, many APAC nations with capital punishment for drug offences are currently reconsidering such severity.
RESEARCH & METHODOLOGY
In conducting this research, we carefully reviewed official government bills and legislation for each country, translated to English where necessary. Additional sources included press briefings, popular media coverage, and industry-tracking sites offering frequent updates on cannabis news.
In some cases, cannabis law and associated penalties for illicit use are quite complex, with contradictory interpretations found across different media outlets. We have done our best to cross-reference accounts, giving greatest credence to federal documentation. Laws are also in flux across many parts of Asia, with bills under discussion and referendum votes pending. As a result, the legal status of cannabis use may change accordingly.
Our analysis covered 14 Asia-Pacific nations and focused on those that had either legalised or decriminalised medical or recreational cannabis use. These top 5 countries were then ranked according to breadth of access and extent of legalisation. Three additional nations were included at the end for their partial development towards increased tolerance.
Please note: Content on Medical Use & Cannabis Research for New Zealand has been updated as of 20 Jan 2020 to reflect legislation that will allow local companies to apply for licenses to cultivate and manufacture medical marijuana starting April 2020.
Health
Survey reveals one-third of Singaporean youth struggle with severe mental health issues
A national study by the Institute of Mental Health reveals that 30.6% of Singaporean youth suffer from severe symptoms of depression, anxiety, or stress, driven by factors like excessive social media use, body image concerns, and cyberbullying. The findings emphasize the need for early intervention and targeted mental health strategies.
A significant portion of Singapore’s youth are experiencing severe mental health challenges, according to a comprehensive national survey conducted by the Institute of Mental Health (IMH).
The National Youth Mental Health Study (NYMHS), released on 19 September 2023, found that 30.6% of individuals aged 15 to 35 reported severe or extremely severe symptoms of depression, anxiety, or stress, with key risk factors including excessive social media use, body shape concerns, and experiences of cyberbullying.
The study, which surveyed 2,600 Singaporean citizens and permanent residents, highlights the growing mental health concerns among Singaporean youth and suggests the need for more targeted interventions and support systems.
Mental Health Issues Prevalent Among Youth
Anxiety was the most common mental health issue, with 27% of respondents reporting severe or extremely severe symptoms, followed by depression (14.9%) and stress (12.9%).
These findings underscore the high prevalence of mental health issues among young people, particularly in those aged 15 to 24, who were more likely to report severe symptoms compared to older participants.
According to the IMH, young people who were female, single, unemployed, or had lower levels of education or household income were more prone to severe mental health symptoms.
For example, youth with monthly household incomes below S$5,000 were more likely to experience severe anxiety.
Key Risk Factors: Social Media, Body Image, and Cyberbullying
The study identified three major factors linked to severe mental health symptoms:
- Excessive Social Media Use: Around 27% of respondents reported using social media for more than three hours daily, which was associated with a significantly higher likelihood of severe mental health issues. Youth with excessive social media use were 1.5 to 1.6 times more likely to experience severe symptoms of depression, anxiety, or stress.
- Body Shape Concerns: About 20.2% of youth had moderate to severe concerns about their body image. These individuals were 4.9 times more likely to experience severe depression, 4.3 times more likely to experience severe anxiety, and 4.5 times more likely to suffer from severe stress. Such concerns were often linked to social media exposure, which can perpetuate unrealistic beauty standards and increase dissatisfaction with one’s body.
- Cyberbullying: One in five youth (21%) reported being victims of cyberbullying. These individuals were approximately twice as likely to report severe mental health symptoms compared to those who had not experienced such harassment. The anonymity and pervasive nature of online bullying exacerbates the mental health toll on young people, according to the study.
Demographics at Higher Risk
The study found that specific demographics were more vulnerable to mental health issues. Young people aged 15 to 24 were more likely to experience anxiety, depression, and stress, particularly females, those who were single, and those with lower levels of education, such as junior college or vocational qualifications.
The Malay ethnic group was also found to have a higher prevalence of severe mental health symptoms compared to other ethnic groups.
Barriers to Seeking Help and Sources of Support
Although about 69.1% of those with severe mental health symptoms sought help—primarily from family and friends—a significant portion of young people hesitated to seek professional support.
The top reasons included concerns about privacy, fear of judgment, and doubts about the effectiveness of professional services.
Among those who sought help, family and friends were the most common sources of support (57.9%), followed by self-help measures (31.1%) and medical services (20.1%).
However, the reluctance to seek professional help highlights the need for continued efforts to destigmatize mental health treatment and increase awareness of available services.
Protective Factors: Resilience, Social Support, and Self-Esteem
The study also identified factors that helped mitigate mental health challenges. Youth who reported higher levels of resilience, perceived social support, and self-esteem were significantly less likely to experience severe symptoms of depression, anxiety, or stress.
This suggests that fostering strong support networks and building resilience in youth could play a critical role in improving their mental well-being.
Government Response and Preventive Measures
The findings of the NYMHS support Singapore’s broader National Mental Health and Well-Being Strategy, launched in October 2023, which adopts a whole-of-government and whole-of-society approach to addressing mental health concerns. Schools have already begun integrating mental health education into their curricula, equipping students with the knowledge and skills to manage their well-being.
Additionally, the government introduced the Parenting for Wellness toolbox in September 2023 to help parents manage their children’s screen time and promote healthy social media usage.
A guide on responsible social media use, expected to be released by mid-2025, will offer further strategies to mitigate the negative impacts of excessive screen time and online harassment.
Future Implications and Policy Development
Associate Professor Swapna Verma, chairman of IMH’s medical board and co-principal investigator of the study, emphasized the importance of early intervention.
“Not all individuals with severe or extremely severe symptoms of depression or anxiety have a clinical condition, but being in such states for a prolonged period of time can be detrimental to their well-being,” she said.
The study’s data will help policymakers and healthcare providers develop more targeted approaches to address the mental health needs of Singapore’s youth, especially those most at risk.
Associate Professor Mythily Subramaniam, IMH’s assistant chairman of medical board (research), stressed the need to pay attention to issues like excessive social media use and cyberbullying, noting their “tremendous impact on youth mental health” and the importance of preventive measures.
Support for Youth Facing Mental Health Challenges
Young people dealing with mental health challenges in Singapore have access to various resources:
- CHAT (Centre of Excellence for Youth Mental Health): CHAT offers a safe and confidential space for youth to seek help through online and face-to-face mental health assessments and support.
- Institute of Mental Health (IMH): IMH provides a comprehensive range of mental health services, including outpatient consultations and inpatient care. Youth in crisis can also seek immediate assistance from the 24-hour Mental Health Helpline at 6389 2222.
- Samaritans of Singapore (SOS): SOS offers emotional support for those feeling distressed or experiencing suicidal thoughts. Their 24-hour hotline is 1767.
- Health Promotion Board’s National Care Hotline: This hotline provides immediate emotional support for those in need and can be reached at 1800-202-6868.
- Counselling Services: School-based counsellors, as well as community-based services such as TOUCH Youth, provide further avenues of support for young people grappling with mental health issues.
Health
Malaysia reports new mpox case in man without recent international travel
Malaysia has confirmed its first mpox case of 2024 in a male patient, the Health Ministry reported. The patient is in isolation and stable, with authorities monitoring his contacts. This brings the total confirmed cases since July 2023 to ten, all from clade II.
MALAYSIA: The Malaysian Health Ministry confirmed a new case of monkeypox (mpox) in a male citizen, marking the country’s first confirmed case of 2024.
The patient, who began showing symptoms on 11 September, is currently in isolation and in stable condition.
The ministry, in a statement issued Tuesday (17 September), revealed that the patient first experienced fever, sore throat, and cough, followed by the appearance of rashes on 12 September.
He has no recent history of international travel within the past 21 days, and authorities are in the process of identifying and monitoring his close contacts, following strict standard operating procedures (SOPs).
“Out of the 58 suspected mpox cases referred to the ministry this year, one case has been confirmed positive for mpox clade II as of 16 September,” the ministry stated.
“All 10 cases reported in Malaysia since July 2023 have been from clade II.”
The Health Ministry had earlier reported that Malaysia recorded a total of nine mpox cases since the first detection on 26 July 2023, with the most recent case reported in November 2023.
All previous cases had links to high-risk activities, but no deaths were reported.
Global Context and National Preparedness
Mpox was declared a Public Health Emergency of International Concern (PHEIC) for the second time on 14 August this year, due to the rapid spread of the clade Ib variant, particularly from the Democratic Republic of Congo (DRC) and neighboring African nations.
In response, Malaysia’s Health Ministry activated its national crisis response centre on 16 August to enhance readiness and coordinate preventive measures.
The ministry advised the public to take precautions, including maintaining personal hygiene and avoiding direct contact with individuals suspected or confirmed to be infected with mpox.
High-risk individuals experiencing symptoms such as fever, swollen lymph nodes, and rashes are urged to seek immediate medical attention.
Mpox is caused by the monkeypox virus (MPVX) and spreads through close contact with symptomatic individuals.
The incubation period is typically between 5 and 21 days, and patients remain contagious until all lesions have dried up and fallen off.
-
Comments2 weeks ago
Netizens question Ho Ching’s praise for Chee Hong Tat’s return from overseas trip for EWL disruption
-
Singapore2 weeks ago
Lee Hsien Yang pays S$619,335 to Ministers Shanmugam and Balakrishnan in defamation suit to protect family home
-
Singapore2 weeks ago
Train services between Jurong East and Buona Vista to remain disrupted until 1 Oct due to new cracks on East-West Line
-
Comments1 week ago
Netizens push back on Ho Ching’s 8-10 million population vision and call for more foreigners
-
Singapore2 weeks ago
Commuters face service disruption on TEL due to train fault following 6-day EWL disruption
-
Comments1 week ago
Dr Chee Soon Juan criticises Ho Ching’s vision for 8-10 million population
-
Singapore1 week ago
PM Lawrence Wong reaffirms government’s commitment to integrity after ex-minister Iswaran’s jail sentence
-
Opinion2 weeks ago
SMRT privatization: Shielding information or strategic restructuring?